Basel Antiarrhythmic Study of Infarct Survival

Burkart F, Pflsterer M, Kiowski W, FoUath F, Burck-hardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990 16 1711-8. 

In the Basel Antiarrhythmic Study of Infarct Survival (BASIS) amiodarone significantly reduced all-cause mortality from 13 to 5%, compared with no antidys-rhythmic drug therapy (37). 

EMIAT (European Myocardial Infarction Amiodarone Trial), CAMIAT (Canadian Amiodarone/Arrhythmia Myocardial Infarction Trial), and BASIS (Basel Antiarrhythmic Study of Infarct Survival) evaluated the use of anpiric amiodarone after myocardial infarction (122,123,133). These studies did not show that amiodarone had a survival advantage however, a small but statistically significant reduction of sudden death (CAMIAT) and arrhythmic events (EMIAT) was observed. 

---